Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    CSL200_
Previous Study | Return to List | Next Study

CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04091737
Recruitment Status : Recruiting
First Posted : September 17, 2019
Last Update Posted : October 4, 2019
Sponsor:
Information provided by (Responsible Party):
CSL Behring

Tracking Information
First Submitted Date  ICMJE September 13, 2019
First Posted Date  ICMJE September 17, 2019
Last Update Posted Date October 4, 2019
Actual Study Start Date  ICMJE October 2, 2019
Estimated Primary Completion Date July 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: September 13, 2019)
  • Number of adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESIs) associated with the administration of CSL200 [ Time Frame: Up to 48 weeks ]
    Adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. Serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, or is medically significant. Adverse event of special interest (AESI) is defined in this study as any of the following: acute immune reactions, autoimmunity to CSL200; malignancy; predominant integration site in presence of malignancy or other abnormality.
  • Number of subjects experiencing AEs, SAEs, and AESIs associated with the administration of CSL200 [ Time Frame: Up to 48 weeks ]
  • Number of AEs, SAEs, and AESIs associated with the collection of CD34+ HSPCs by apheresis after mobilization with plerixafor [ Time Frame: Up to 6 weeks ]
  • Number of subjects experiencing AEs, SAEs, and AESIs associated with the collection of CD34+ HSPCs by apheresis after mobilization with plerixafor [ Time Frame: Up to 6 weeks ]
  • Number of AEs, SAEs, and AESIs associated with reduced intensity conditioning with melphalan [ Time Frame: Up to 3 weeks ]
  • Number of subjects experiencing AEs, SAEs, and AESIs associated with reduced intensity conditioning with melphalan [ Time Frame: Up to 3 weeks ]
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT04091737 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: September 13, 2019)
  • Total by-subject number of CD34+ HSPCs collected in total and in each apheresis session [ Time Frame: Up to 2 days ]
    Collection of CD34+ HSPCs by apheresis after mobilization with plerixafor assessed by CD34+ HSPCs collected
  • Number of subjects receiving plerixafor and number of plerixafor doses administered by subject [ Time Frame: Up to 2 days ]
    Collection of CD34+ HSPCs by apheresis after mobilization with plerixafor assessed by plerixafor administrations
  • Number of subjects undergoing apheresis and number of apheresis sessions by subject [ Time Frame: Up to 2 days ]
    Collection of CD34+ HSPCs by apheresis after mobilization with plerixafor assessed by apheresis sessions
  • The number of subjects undergoing reduced intensity conditioning with melphalan and able to receive CSL200 [ Time Frame: 2 days ]
    Reduced intensity conditioning assessed by subjects receiving melphalan
  • Number of subjects receiving CSL200 [ Time Frame: 1 day ]
  • By-subject number of separate CSL200 drug products administered [ Time Frame: 1 day ]
  • Number of CSL200 CD34+ HSPCs/kg administered by subject and by CSL200 drug product [ Time Frame: 1 day ]
  • By-subject total number and percentage of CD34+ HSPCs transduced with CAL-H [ Time Frame: Up to 48 weeks ]
  • Vector copy number (VCN) [ Time Frame: Up to 48 weeks ]
    VCN will be determined by using the average number of CAL-H vector genomes per cell
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease
Official Title  ICMJE A Phase 1 Pilot Study to Evaluate the Safety and Feasibility of Gene Therapy With CSL200 (Autologous Enriched CD34+ Cell Fraction That Contains CD34+ Cells Transduced With Lentiviral Vector Encoding Human γ-GlobinG16D and Short-Hairpin RNA734) in Adult Subjects With Severe Sickle Cell Disease
Brief Summary This is a phase 1 pilot study of CSL200 in adult subjects with severe sickle cell disease. The primary objectives of this study are to evaluate the safety of the following: collection of CD34+ hematopoietic stem / progenitor cells by apheresis after mobilization with plerixafor, reduced intensity conditioning with melphalan, and administration of CSL200.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Anemia, Sickle Cell
Intervention  ICMJE Biological: Autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734
  • Cryopreserved formulated autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734 in a bag for infusion
  • Plerixafor to mobilize hematopoietic stem cells prior to each apheresis
  • Single dose melphalan before administration of CSL200
Other Name: CSL200
Study Arms  ICMJE Experimental: CSL200
Autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734
Intervention: Biological: Autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: September 13, 2019)
3
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE July 2021
Estimated Primary Completion Date July 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Diagnosis of sickle cell disease with the homozygous HbSS or an HbSβ thalassemia variant (ie, HbSβ0 thalassemia or HbSβ+ thalassemia) genotype, confirmed by hemoglobin studies.
  • Fetal hemoglobin (HbF) ≤ 15%.
  • Severe sickle cell disease symptomatology, defined as any one or more of the following:

    1. ≥ 2 episodes of acute chest syndrome in the last 2 years.
    2. ≥ 3 episodes of severe pain events requiring a visit to a medical facility and treatment with opioids in the last 2 years.
    3. > 2 episodes of recurrent priapism in the last 2 years.
    4. Red-cell alloimmunization (> 2 antibodies) during long-term transfusion therapy (lifetime history).
    5. Chronic transfusions for primary or secondary prophylaxis (lifetime history).
    6. Trans-thoracic echocardiograph evidence of tricuspid valve regurgitant jet velocity ≥ 2.7 m/sec (lifetime history).
    7. Clinically significant neurologic event (eg, ischemic stroke) or any neurological deficit lasting > 24 hours.

Exclusion Criteria:

  • Hypoxanthine-guanine phosphoribosyl transferase (HPRT) deficiency.
  • Thiopurine S-methyltransferase (TPMT) deficiency.
  • Alpha thalassemia.
  • Serum ferritin ≥ 2500 ng/mL.
  • Inadequate bone marrow function, defined as at least 1 of the following:

    1. Absolute neutrophil count < 1000/µL.
    2. Platelet count < 120,000/µL.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 45 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Trial Registration Coordinator 610-878-4000 clinicaltrials@cslbehring.com
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04091737
Other Study ID Numbers  ICMJE CSL200_1001
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description:

CSL will consider requests to share Individual Patient Data (IPD) from systematic review groups or bona-fide researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.

Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD.

If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.

Supporting Materials: Study Protocol
Supporting Materials: Statistical Analysis Plan (SAP)
Time Frame: IPD requests may be submitted to CSL no earlier than 12 months after publication of the results of this study via an article made available on a public website.
Access Criteria:

Requests may only be made by systematic review groups or bona-fide researchers whose proposed use of the IPD is non-commercial in nature and has been approved by an internal review committee.

An IPD request will not be considered by CSL unless the proposed research question seeks to answer a significant and unknown medical science or patient care question as determined by CSL's internal review committee.

The requesting party must execute an appropriate data sharing agreement before IPD will be made available.

Responsible Party CSL Behring
Study Sponsor  ICMJE CSL Behring
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Study Director CSL Behring
PRS Account CSL Behring
Verification Date October 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP